Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

2(40.0%)

Phase 2

2(40.0%)

N/A

1(20.0%)

5Total

Phase 1(2)

Phase 2(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT02157506Phase 2Completed

A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure

Role: collaborator

NCT02819271Phase 1Completed

A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers

Role: collaborator

NCT01096043Phase 2Completed

A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure

Role: collaborator

NCT01092325Phase 1Completed

Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure

Role: collaborator

NCT02350114Not ApplicableCompleted

An Observational Study of the Functional Capacity of Heart Failure

Role: collaborator

All 5 trials loaded